Unlocking The Potential of ACTG1P4: A Comprehensive Overview of A Drug Target and Biomarker

Target Name: ACTG1P4

NCBI ID: G648740

ACTG1P4

Other Name(s): actin gamma 1 pseudogene 4 | ACTGP4 | Actin gamma 1 pseudogene 4

Unlocking The Potential of ACTG1P4: A Comprehensive Overview of A Drug Target and Biomarker

Exploring the Potential Drug Target and Biomarker for ACTG1P4: Unraveling the Biology and Therapeutic Potential of Actin Gamma 1 Pseudogene 4

ACTG1P4, also known as actin gamma 1 pseudogene 4, is a gene located on chromosome 16q22. It has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. This gene has been associated with various physiological functions, including cell adhesion, migration, and invasion, which have implications for its potential therapeutic applications.

Purpose of the Article

The purpose of this article is to provide a comprehensive overview of ACTG1P4, including its biology, expression, and potential therapeutic applications. The article will focus on the biological functions of ACTG1P4, its expression in various tissues and cell types, and its potential as a drug target and biomarker.

Biology and Expression of ACTG1P4

ACTG1P4 is a member of the ACTG1 family, which includes several genes involved in actin function. These genes are involved in the regulation of actin dynamics, stability, and organization, which are critical for various cellular processes, including cell adhesion, migration, and invasion.

ACTG1P4 has been identified in various tissues and cell types, including human placenta, breast tissue, and various types of cancer cells. It has been shown to be expressed in high levels in these tissues and can be used as a reliable biomarker for these diseases.

Potential Therapeutic Applications

ACTG1P4 has been identified as a potential drug target due to its involvement in various cellular processes that are crucial for disease progression. Several studies have shown that inhibiting the activity of ACTG1P4 can lead to therapeutic effects in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

One of the potential therapeutic applications of ACTG1P4 is its potential as a cancer therapeutic. Several studies have shown that inhibiting the activity of ACTG1P4 can lead to a reduction in cancer cell proliferation and survival. This is because ACTG1P4 is involved in the regulation of actin dynamics, which are critical for cell migration and invasion.

Another potential therapeutic application of ACTG1P4 is its potential as a neurodegenerative disorder biomarker. Several studies have shown that ACTG1P4 is expressed in the brains of individuals with neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. This suggests that ACTG1P4 may be a useful biomarker for these disorders.

Finally, ACTG1P4 has also been identified as a potential therapeutic target for autoimmune diseases. Several studies have shown that inhibiting the activity of ACTG1P4 can lead to therapeutic effects in autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.

Conclusion

In conclusion, ACTG1P4 is a gene that has been identified as a potential drug target and biomarker for various diseases. Its biology and expression have been extensively studied, and its potential therapeutic applications have been explored in various models. Further research is needed to fully understand the role of ACTG1P4 in disease progression and to develop effective therapies based on its potential as a drug target and biomarker.

Protein Name: Actin Gamma 1 Pseudogene 4

The "ACTG1P4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACTG1P4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets